Needham & Company LLC Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $17.00

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its price target lifted by investment analysts at Needham & Company LLC from $15.00 to $17.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Needham & Company LLC's target price would suggest a potential upside of 70.34% from the company's previous close.

BCRX has been the topic of a number of other reports. JMP Securities reissued a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target on the stock. Evercore ISI boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock traded up $0.06 on Tuesday, reaching $9.98. The company had a trading volume of 7,606,302 shares, compared to its average volume of 2,989,382. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -16.36 and a beta of 1.08. The firm's 50-day moving average price is $7.87 and its two-hundred day moving average price is $7.89. BioCryst Pharmaceuticals has a 1 year low of $5.34 and a 1 year high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same period last year, the firm earned $0.28 earnings per share. The firm's revenue for the quarter was up 40.8% compared to the same quarter last year. As a group, analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently modified their holdings of BCRX. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals in the first quarter worth approximately $32,000. New Age Alpha Advisors LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth $62,000. R Squared Ltd boosted its position in BioCryst Pharmaceuticals by 84.2% during the first quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company's stock valued at $88,000 after purchasing an additional 5,335 shares in the last quarter. Jupiter Asset Management Ltd. raised its holdings in BioCryst Pharmaceuticals by 82.4% in the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after purchasing an additional 971,040 shares in the last quarter. Finally, XTX Topco Ltd lifted its position in shares of BioCryst Pharmaceuticals by 314.8% during the first quarter. XTX Topco Ltd now owns 87,389 shares of the biotechnology company's stock valued at $655,000 after buying an additional 66,320 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.